Key Highlights
● SXTC shares plunged 87.86% to $0.34 in Thursday’s October 8 session, far outside ordinary volatility.
● The company announced a $12 million registered direct offering of 8,000,000 shares at $1.50 each.
● Each of 8,000,000 warrants carries a zero cash exercise option for up to nine shares.
China SXT Pharmaceuticals (NASDAQ:SXTC) was among the steepest decliners on the US tape during the Thursday, October 8, 2026 session, closing at $0.34 after a one-day decline of 87.86%. The same day, the company announced a $12 million registered direct offering. A move of that magnitude sits far outside the range of ordinary market Volatility and, for a company of this size, often reflects a structural event in the share count or the float rather than a change in the underlying business.
A $12 Million Registered Direct Offering
China SXT Pharmaceuticals announced on October 8 that it had entered into a definitive agreement with certain institutional investors for the purchase and sale of an aggregate of 8,000,000 Class A ordinary shares, no par value, or pre-funded warrants in lieu thereof, at a purchase price of $1.50 per share in a registered direct offering. Aggregate gross proceeds are expected to be approximately $12 million before Placement agent fees and other offering expenses. The offering is expected to close on or about October 9, 2026, subject to customary closing conditions, with Univest Securities, LLC acting as sole placement agent.
The offering is being made under a shelf registration statement on Form F-3 that was previously filed with the SEC and became effective on December 1, 2025.
Warrants With a Zero Cash Exercise Option
The company also agreed to issue the same investors 8,000,000 warrants with an exercise price of $1.50 per share. The warrants are immediately exercisable upon issuance and have a one-year term. Each Warrant has a zero cash exercise option permitting the holder to acquire up to nine Class A shares, which, if applied across all 8,000,000 warrants, would imply up to 72 million shares, compared with 8,000,000 shares in the offering itself. Investors also have an additional purchase right to acquire up to $12 million of securities on the same terms during the 30-day period after closing.
The Close Versus the Offering Price
The shares closed at $0.34, well below the $1.50 per-share purchase price in the offering and the $1.50 warrant exercise price. The announcement came on the same session in which the shares fell 87.86%. A large issuance relative to a nano-cap’s existing share base can pressure the price, though the company’s announcement does not itself describe the market’s reaction. In a low-float name, a thin pool of freely tradable shares can also amplify ordinary selling into an outsized percentage move.
A History of Reverse Splits
China SXT Pharmaceuticals has a documented pattern of reverse share splits, including a one-for-eighty reverse split that took effect earlier in 2026, preceded over prior periods by additional one-for-twenty and one-for-twenty-five consolidations. Companies trading at these price levels frequently turn to reverse splits to maintain exchange listing standards and to dilutive Capital raises to fund operations. Each of those actions can trigger sharp, discontinuous price moves that look extreme on a percentage basis but stem from changes to the Capital Structure rather than from fresh operating news.
The Business Behind the Ticker
Founded in 2005 and headquartered in Taizhou City, Jiangsu Province, China, China SXT Pharmaceuticals is a pharmaceutical company focused on the research, development, manufacture, Marketing and sales of traditional Chinese medicine pieces, a type of Traditional Chinese Medicine that has been processed to be ready for use. The company is led by Chief Executive Officer Feng Zhou.
A Risk-Off Tape Offers No Cushion
The broader market backdrop did little to help speculative, lightly capitalized names. The session carried a distinctly risk-off tone, with the Nasdaq Composite falling 1.25% to close near 27,193 as a semiconductor and artificial-intelligence-infrastructure selloff weighed on technology sentiment. The S&P 500 slipped 0.47% to roughly 7,765, while the Dow Jones Industrial Average edged up 0.10% to about 51,232, buoyed by energy and defensive strength. Against a tape where investors were trimming risk, the most fragile and thinly traded securities tend to see the sharpest downside, and names priced at cents offer little cushion when sellers step in.
Rates Add Pressure on Equity-Funded Issuers
Context around interest rates adds to the pressure on this category. The ten-year Treasury Yield held near 5.3% to 5.35%, close to multidecade highs, a level that raises the discount applied to companies whose value rests largely on future, unproven cash flows. Micro-cap and nano-cap issuers that depend on repeated Equity financing are particularly sensitive to that environment, because a higher Cost of Capital and a weaker appetite for speculative risk make each subsequent raise more dilutive to existing holders.
A Collapse Far Below the Offering Terms
China SXT Pharmaceuticals’ shares settled at $0.34, far below the $1.50 per-share terms of the offering announced that day. The structure of the deal, which pairs a $12 million raise with warrants carrying a zero cash exercise option, put the share count at the center of the day’s story, set against a risk-off tape and a history of repeated reverse splits.






Please wait processing your request...